Literature DB >> 8456048

Opiate addiction and the locus coeruleus. The clinical utility of clonidine, naltrexone, methadone, and buprenorphine.

M S Gold1.   

Abstract

Detoxification from opiate addiction has been a medical problem for as long as opiate drugs have been available. Treatment before the discovery of clonidine involved giving another opioid drug with less dangerous consequences of chronic use, such as the long-acting and orally administered once a day methadone, for another opioid mu agonist like heroin, which must be taken intravenously many times a day, thus making rehabilitation, work, and avoidance of hepatitis, HIV, and other illnesses difficult. Although methadone has proved to be very beneficial, it still has significant abuse potential. Naltrexone, because it blocks the effects of all opiates, has facilitated the transformation from addiction to a drug-free state for many recovering addicts. By alleviating withdrawal symptoms and by lessening the detoxification period, clonidine similarly has improved the prospect of recovery from opiate addiction. Relapse, whether withdrawal is treated with clonidine or other new agents or not, occurs with great regularity because repeated opiate use can induce a new acquired drive state--the drive for opiates. In addition, with powerful withdrawal symptoms during abstinence, opiate relapse is difficult to prevent without an adequate treatment program. The efficacy of clonidine and other medical magic bullets for withdrawal distress needs to be given as part of a long-term recovery program which not only allows the brain to re-establish normal homeostatic changes in the drug-free state but also provides sufficient motivation for new approaches to achieving and sustaining pleasurable existence.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8456048

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  11 in total

Review 1.  The medical management of adolescent heroin dependence.

Authors:  A B Rowan; P J Fudala; J Mulligan
Journal:  Curr Psychiatry Rep       Date:  2000-12       Impact factor: 5.285

Review 2.  Clinical safety of 1500 mg oral naltrexone overdose.

Authors:  Albert Stuart Reece
Journal:  BMJ Case Rep       Date:  2010-09-07

Review 3.  Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal.

Authors:  J L Scavone; R C Sterling; E J Van Bockstaele
Journal:  Neuroscience       Date:  2013-04-24       Impact factor: 3.590

4.  Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?

Authors:  Kenneth Blum; Thomas J H Chen; John Bailey; Abdalla Bowirrat; John Femino; Amanda L C Chen; Thomas Simpatico; Siobhan Morse; John Giordano; Uma Damle; Mallory Kerner; Eric R Braverman; Frank Fornari; B William Downs; Cynthia Rector; Debmayla Barh; Marlene Oscar-Berman
Journal:  Mol Neurobiol       Date:  2011-09-24       Impact factor: 5.590

Review 5.  Is clonidine an effective smoking cessation therapy?

Authors:  S G Gourlay; N L Benowitz
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

6.  Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine.

Authors:  Zoe M Weinstein; Debbie M Cheng; Emily Quinn; David Hui; Hyunjoong Kim; Gabriela Gryczynski; Jeffrey H Samet
Journal:  Drug Alcohol Depend       Date:  2016-11-05       Impact factor: 4.492

7.  Withdrawal from Buprenorphine/Naloxone and Maintenance with a Natural Dopaminergic Agonist: A Cautionary Note.

Authors:  Kenneth Blum; Marlene Oscar-Berman; John Femino; Roger L Waite; Lisa Benya; John Giordano; Joan Borsten; William B Downs; Eric R Braverman; Raquel Loehmann; Kristina Dushaj; David Han; Thomas Simpatico; Mary Hauser; Debmalya Barh; Thomas McLaughlin
Journal:  J Addict Res Ther       Date:  2013-04-23

8.  Genospirituality: Our Beliefs, Our Genomes, and Addictions.

Authors:  Kenneth Blum; Benjamin Thompson; Marlene Oscar-Berman; John Giordano; Eric Braverman; John Femino; Debmayla Barh; William Downs; Thomas Smpatico; Stephen Schoenthaler
Journal:  J Addict Res Ther       Date:  2013-10-10

9.  Current and emerging pharmacotherapeutic options for smoking cessation.

Authors:  Kristin V Carson; Malcolm P Brinn; Thomas A Robertson; Rachada To-A-Nan; Adrian J Esterman; Matthew Peters; Brian J Smith
Journal:  Subst Abuse       Date:  2013-05-23

Review 10.  Clonidine for smoking cessation.

Authors:  S G Gourlay; L F Stead; N L Benowitz
Journal:  Cochrane Database Syst Rev       Date:  2004
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.